

August 8, 2024

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter ended June 30, 2024.

Thanking you,

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Press Release

AstraZeneca Pharma India Limited Reports Strong Q1 Results, Achieving 31% Growth for Quarter ended June 30, 2024

Bangalore, August 8, 2024: AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, is pleased to announce its financial results for the first quarter ended June 30, 2024. The Company reported strong financial performance, achieving a 31% increase in revenue compared to the same period last year. This growth is testament to our unwavering commitment to addressing the unmet medical needs of patients in India and beyond.

Financial performance highlights for Q1'2024

- **Revenue from Operation** for the quarter stood at INR 3,875.2 million with substantial 31% increase demonstrating Company's focus on improving access to patients.
- **Profit before exceptional item and tax** is INR 424 million (11% of the total Income) reflecting the Company's efforts on driving profitable growth.
- **Loss after exceptional item and tax** is INR 117.9 million (-3% of total income) due to booking of provisions associated with exit of factory site announced in this quarter.

Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations."

Bhavana Agrawal, Chief Finance Officer, added, "It's a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of Company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders."

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science for the benefit of people, society, and the planet. The Company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.

Key milestones achieved for Q1 '2024:

- Partnered with Vaayu Chest & Sleep Center to elevate the standard of respiratory care for severe asthma patients by setting up Center of Excellence (COE) in Bengaluru.

Recognitions:

- Recognized as one of "**India's Best Organizations in Innovation**" by ET Now
- Awarded '**Pharma InHouse Legal Team of the Year**' at the 13th Annual Legal Era - Indian Legal Awards 2023-24
- Amarpreet Kaur Ahuja, Country HR Director, was featured among "**The Powerhouses of Indian HR: Women Driving Change and Innovation**" by Indian Conventions.

About AstraZeneca:

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: www.astrazeneca.com/india, or connect with us on [LinkedIn](#) and [X.com](#).